Platelet News and Research

RSS

Sunesis Pharmaceuticals enrolls 113 patients in voreloxin REVEAL-1 trial

Sunesis Pharmaceuticals, Inc. today reported that it has completed enrollment in the REVEAL-1 (Response Evaluation of VorEloxin in AmL) trial, a Phase 2 dose regimen optimization trial of single agent voreloxin in newly diagnosed elderly acute myeloid leukemia (AML) patients who are unlikely to benefit from standard induction chemotherapy. A total of 113 patients were enrolled and dosed according to one of three dosing schedules.

30 Oct 2009

Donor testing services from LABS

LABS Inc., one of the premier transplant reference and consultative laboratories in the country, announced today that it will begin offering a full range of donor testing services to the transfusion medicine and blood services industry. LABS Inc.'s acquisition of Research and Diagnostic Laboratories in October brings its expertise to blood collection programs nationwide.

27 Oct 2009

CHMP grants positive opinion to extend the use of Angiox to patients undergoing PCI

The Medicines Company announced today that the Committee for Medicinal Products for Human Use (CHMP) has granted a positive opinion applicable to all Member States of the European Union/European Economic Area that will extend the use of Angiox (bivalirudin) to include patients with heart attacks (so-called ST segment elevation myocardial infarction (STEMI)) undergoing emergency heart procedures called primary percutaneous coronary intervention (PCI).

24 Oct 2009

Orthopedic surgeon to present latest findings on stem cells and plasma rich platelet therapy

Joseph Purita M.D., a well known Orthopedic Surgeon from Florida has announced that plans are being made with the Orthopedic Academies in Sao Paulo Brazil to present his latest findings on the use of stem cells and plasma rich platelet therapy in the treatment of certain bone and joint problems.

24 Oct 2009

Rich Plasma and Stem Cell therapies improve orthopedic conditions

Although stem cells sounds innovative and cutting edge, this therapy has been around for quite some time. In today's advanced medical climate stem cells are being used to treat many orthopedic conditions including osteoarthritis of the hip knee and shoulder, partial tears of tendons, muscles, and ligaments including rotator cuff tears, and various back conditions including disc herniations.

19 Oct 2009

Cardium Therapeutics reports positive findings from Excellarate Phase 1/2 clinical study

Cardium Therapeutics today announced the publication of positive findings from the open label multi-center Phase 1/2 clinical study of Excellarate(TM) (GAM501, Ad5PDGF-B / 2.6% collagen), its product candidate for the potential treatment of non-healing diabetic foot ulcers.

19 Oct 2009

Research study reveals SFSGD in EGD individuals with GRBWR below 0.8%

Small-for-size graft dysfunction (SFSGD) following living-related liver transplantation (LRLT) is characterized by early graft dysfunction (EGD) when the graft-to-recipient body weight ratio (GRBWR) is below 0.8%.

19 Oct 2009

Positive results from Protalix BioTherapeutics Phase III UPLYSO clinical trial

Protalix BioTherapeutics, Inc., announced today positive top-line results from the Company's pivotal Phase III clinical trial of UPLYSO (taliglucerase alfa, previously referred to as prGCD) in treatment naive patients diagnosed with Gaucher disease.

15 Oct 2009

Study shows the impact of blood cell development on human diseases

A new genome-wide association study published today in Nature Genetics begins to uncover the basis of genetic variations in eight blood measurements and the impact those variants can have on common human diseases. Blood measurements, including the number and volume of cells in the blood, are routinely used to diagnose a wide range of disorders, including anaemia, infection and blood cell cancers.

12 Oct 2009

NHLBI awards $16.7 million to develop new clinical strategies in stem cell therapy

9 Oct 2009

Hutchinson Center scientists awarded $16.7M to develop progenitor and stem cell tools

The National Heart, Lung and Blood Institute has awarded a total of $16.7 million to Irwin Bernstein, M.D., and Beverly Torok-Storb, Ph.D., both members of the Clinical Research Division at Fred Hutchinson Cancer Research Center. The Hutchinson Center grants represent part of a $170 million effort involving 18 teams of research scientists dedicated to developing stem- and progenitor-cell tools and therapies.

8 Oct 2009

The Top 10 Medical Innovations for 2010 announced at Cleveland Clinic Medical Innovation Summit

Cleveland Clinic's Top 10 Medical Innovations for 2010 list features a wide range of new techniques and therapies that are being developed to treat everything from deafness and Parkinson's disease to pneumonia and sleep disorders.

7 Oct 2009

NYBC encourages people to organize community blood drives

With the school season underway, New York Blood Center would like to encourage students, teachers and faculty to please organize blood drives at their schools, a process that teaches community service and leadership skills, and offers a learning experience for both students and the surrounding community.

6 Oct 2009

PDT-PCI combination with ENVIRON Surgical Roll-CIT effective for treating facial acne scars

The appearance of facial acne scars showed greater improvement with a combination treatment of photodynamic therapy (PDT) and percutaneous collagen induction (PCI or medical needling) with the ENVIRON® Surgical Roll-CIT(TM) compared to PDT alone.

5 Oct 2009

New study reports PRP treatment and its use in sports medicine

Platelet -rich plasma (PRP) is currently used as an alternative treatment method for several common orthopaedic-related sports medicine conditions.

3 Oct 2009

Cardium announces positive results from the Phase 1 / 2 clinical study of Excellarate

Cardium Therapeutics announced plans to report on preliminary safety and efficacy data from its Matrix Phase 2b Excellarate clinical study. Based on guidance from Cardium's independent clinical data management company which is currently completing the statistical analysis of all data for the Matrix clinical trial, Cardium expects to receive the locked unblinded data set and be in position to announce preliminary results on or before October 14, 2009.

3 Oct 2009

Novartis Oncology, Amgen, GlaxoSmithKline and Veridex honored with 2009 Prix Galien Award

The Prix Galien USA committee celebrated members of the science and biotechnology industries last night for the development and discovery of drugs and technologies that improve the human condition.

1 Oct 2009

National Institutes of Health awards $16.8 million grant to Hutchinson Center/UW group

The National Heart, Lung and Blood Institute of the National Institutes of Health has awarded a $16.8 million, seven-year grant to launch a bicoastal research partnership between Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium and Children's Hospital of Philadelphia.

30 Sep 2009

Folotyn approved for the treatment of Peripheral T-Cell Lymphoma

The U.S. Food and Drug Administration has approved Folotyn (pralatrexate), the first treatment for a form of cancer known as Peripheral T-cell Lymphoma (PTCL), an often aggressive type of non-Hodgkins lymphoma.

25 Sep 2009

Interim data from GORE PROPATEN Vascular Graft studies presented at the 2009 vascular meeting

W. L. Gore & Associates (Gore) today announced that several physicians recently presented interim data from ongoing GORE PROPATEN® Vascular Graft studies to clinical audiences at the 2009 annual vascular meeting. The conference, the premier event hosted by the Society for Vascular Surgery (SVS), was held in mid-June in Denver, Colorado. One physician reported primary patency rates as high as 100 percent for below-knee bypasses.

17 Sep 2009

Platelet News and Research

Sunesis Pharmaceuticals enrolls 113 patients in voreloxin REVEAL-1 trial

Donor testing services from LABS

CHMP grants positive opinion to extend the use of Angiox to patients undergoing PCI

Orthopedic surgeon to present latest findings on stem cells and plasma rich platelet therapy

Rich Plasma and Stem Cell therapies improve orthopedic conditions

Cardium Therapeutics reports positive findings from Excellarate Phase 1/2 clinical study

Research study reveals SFSGD in EGD individuals with GRBWR below 0.8%

Positive results from Protalix BioTherapeutics Phase III UPLYSO clinical trial

Study shows the impact of blood cell development on human diseases

NHLBI awards $16.7 million to develop new clinical strategies in stem cell therapy

Hutchinson Center scientists awarded $16.7M to develop progenitor and stem cell tools

The Top 10 Medical Innovations for 2010 announced at Cleveland Clinic Medical Innovation Summit

NYBC encourages people to organize community blood drives

PDT-PCI combination with ENVIRON Surgical Roll-CIT effective for treating facial acne scars

New study reports PRP treatment and its use in sports medicine

Cardium announces positive results from the Phase 1 / 2 clinical study of Excellarate

Novartis Oncology, Amgen, GlaxoSmithKline and Veridex honored with 2009 Prix Galien Award

National Institutes of Health awards $16.8 million grant to Hutchinson Center/UW group

Folotyn approved for the treatment of Peripheral T-Cell Lymphoma

Interim data from GORE PROPATEN Vascular Graft studies presented at the 2009 vascular meeting

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News